8-K: NRx Subsidiary HOPE Completes Dura Medical Acquisition, Expands Florida Network

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, has completed the acquisition of Dura Medical, expanding its interventional psychiatry clinic network across Florida's West Coast.

Summary

• HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc., has completed the acquisition of Dura Medical.
• Dura Medical, with existing locations in Naples and Ft. Myers, Florida, offers precision psychiatry services including Ketamine Therapy, Transcranial Magnetic Stimulation (TMS), Spravato, and Stellate Ganglion Blocks.
• The acquisition, combined with pending acquisitions of Neurospa TMS and Cohen & Associates, is planned to provide contiguous coverage at more than 8 locations along Florida's West Coast.
• Dura Medical is revenue generating and EBITDA positive.
• Stephen Durand, CRNA, a US Army Veteran and founder of Dura Medical, has been appointed Director of Florida Clinic Operations for HOPE Therapeutics.
• Dura Medical participates in the Veterans Affairs Community Cares Network (VA CCN), providing interventional psychiatry programs to military veterans.

Sentiment

Score: 8

Explanation: The completion of the Dura Medical acquisition is a significant positive step for HOPE Therapeutics and NRx Pharmaceuticals, expanding their clinical network with a revenue-generating and EBITDA-positive entity, and addressing critical mental health needs. The strategic expansion and integration of experienced management are strong indicators of future growth.

Positives

• Acquisition of Dura Medical expands HOPE Therapeutics' clinical care delivery network in Florida.
• Dura Medical is a revenue-generating and EBITDA-positive entity, contributing positively to financial performance.
• The expanded network will offer a comprehensive range of precision psychiatry services, including advanced therapies like Ketamine and TMS, addressing critical mental health needs.
• The acquisition strengthens the company's commitment to serving veterans through participation in the VA Community Cares Network.
• Stephen Durand, an experienced pioneer in the field, joins HOPE Therapeutics' leadership as Director of Florida Clinic Operations, bringing valuable expertise.

Risks

• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and other factors beyond the company's control.
• Future regulatory determinations and outcomes are uncertain and cannot be predicted.
• Risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity could materially affect actual results.

Future Outlook

HOPE Therapeutics plans to expand its network of interventional psychiatry clinics throughout the Florida Peninsula and beyond, aiming to treat more than 10,000 people by 2026. NRx Pharmaceuticals continues to develop its NMDA platform therapeutics, NRX-100 and NRX-101, for central nervous system disorders, including suicidal depression, chronic pain, and PTSD, with ongoing regulatory filings.

Management Comments

• "The entire Dura family is excited to bring our mission to the HOPE Network and I look forward to helping lead HOPEs expansion throughout Florida. Dura Medical was founded with the mission to reduce suicide in our community and we aim to treat more than 10,000 people by 2026. Combining with HOPE is a tremendous step toward achieving this goal." Stephen Durand, Founder of Dura Medical.
• "Steve Durand is a pioneer in combining the use of psychedelic medications with TMS and other neuroplastic technologies for advancing the treatment of suicidal depression and PTSD in Southwest Florida. He has brought his experience as an Army veteran to building Duras tradition of excellence and commitment to patient care for civilians and veterans alike. His commitment and sense of purpose align perfectly with HOPEs vision for our Florida network. We look forward to Steves partnership as we continue to build our network throughout the State of Florida and beyond." Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics.

Industry Context

This acquisition positions NRx Pharmaceuticals and HOPE Therapeutics to capitalize on the growing demand for advanced mental health treatments, particularly interventional psychiatry services like ketamine therapy and TMS, which are gaining acceptance for severe depression and PTSD. The focus on veterans aligns with a critical public health need and a significant market segment, reflecting a broader trend of integrating specialized clinics into larger healthcare networks to provide comprehensive care.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased revenue, market share, and strategic growth for NRx Pharmaceuticals through its subsidiary HOPE Therapeutics.
• Patients: Expanded access to advanced interventional psychiatry services for severe depression, PTSD, and chronic pain, particularly for veterans in Florida.
• Employees: Dura Medical staff are integrated into the HOPE Network, with founder Stephen Durand taking a key leadership role.
• Regulatory Authorities: Successful receipt of final regulatory clearance from Florida's Agency for Health Care Administration demonstrates compliance.

Next Steps

• Integration of Dura Medical into HOPE Therapeutics' network.
• Completion of pending acquisitions of Neurospa TMS and Cohen & Associates.
• Expansion of HOPE's interventional psychiatry clinic network throughout Florida and potentially beyond.
• Continued development and regulatory filings for NRx Pharmaceuticals' drug candidates, NRX-100 and NRX-101.

Key Dates

Recommendation

The acquisition of Dura Medical is a strategic positive for NRx Pharmaceuticals, expanding its subsidiary HOPE Therapeutics' footprint with a revenue-generating and EBITDA-positive asset in the high-demand interventional psychiatry market. This move enhances the company's clinical care delivery network, complements its biopharmaceutical pipeline, and positions it for growth in addressing critical mental health needs, particularly for veterans. The planned further expansion in Florida and the stated goal of treating 10,000 people by 2026 indicate strong growth potential.

Keywords

NRx Pharmaceuticals, HOPE Therapeutics, Dura Medical, Acquisition, Interventional Psychiatry, Ketamine Therapy, Transcranial Magnetic Stimulation, PTSD, Depression, Florida, Mental Health, Biopharmaceutical, Veterans Affairs